James Robinson

6.7k total citations
34 papers, 1.9k citations indexed

About

James Robinson is a scholar working on Psychiatry and Mental health, Epidemiology and Physiology. According to data from OpenAlex, James Robinson has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Psychiatry and Mental health, 7 papers in Epidemiology and 7 papers in Physiology. Recurrent topics in James Robinson's work include Schizophrenia research and treatment (9 papers), Attention Deficit Hyperactivity Disorder (6 papers) and Substance Abuse Treatment and Outcomes (5 papers). James Robinson is often cited by papers focused on Schizophrenia research and treatment (9 papers), Attention Deficit Hyperactivity Disorder (6 papers) and Substance Abuse Treatment and Outcomes (5 papers). James Robinson collaborates with scholars based in United States, Canada and Australia. James Robinson's co-authors include Robert A. Rosenheck, Kim T. Mueser, Mary F. Brunette, Christoph U. Correll, Jean Addington, Sue E. Estroff, John M. Kane, David L. Penn, Patricia Marcy and Nina R. Schooler and has published in prestigious journals such as Science, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

James Robinson

33 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Robinson United States	22	898	533	288	287	234	34	1.9k
Jonna Perälä Finland	26	1.3k 1.5×	675 1.3×	177 0.6×	404 1.4×	183 0.8×	42	2.5k
Jorge A. Cervilla Spain	29	1.1k 1.2×	973 1.8×	133 0.5×	310 1.1×	234 1.0×	109	2.7k
Laura J. Fochtmann United States	26	1.6k 1.8×	865 1.6×	216 0.8×	271 0.9×	122 0.5×	58	2.8k
Paul Summergrad United States	26	605 0.7×	566 1.1×	104 0.4×	206 0.7×	291 1.2×	79	2.1k
J. Steven Lamberti United States	27	1.3k 1.4×	932 1.7×	95 0.3×	318 1.1×	169 0.7×	66	2.2k
Petter Andreas Ringen Norway	25	1.7k 1.9×	510 1.0×	147 0.5×	165 0.6×	183 0.8×	52	2.3k
Ana Fresán Mexico	23	843 0.9×	967 1.8×	118 0.4×	490 1.7×	183 0.8×	216	2.4k
Alexandre Berney Switzerland	25	658 0.7×	452 0.8×	262 0.9×	99 0.3×	145 0.6×	91	2.5k
Teresa Bascarán Spain	22	622 0.7×	580 1.1×	138 0.5×	177 0.6×	62 0.3×	51	1.4k
Baruch Spivak Israel	25	749 0.8×	492 0.9×	162 0.6×	112 0.4×	100 0.4×	76	1.8k

Countries citing papers authored by James Robinson

Since Specialization

Citations

This map shows the geographic impact of James Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Robinson more than expected).

Fields of papers citing papers by James Robinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Robinson. The network helps show where James Robinson may publish in the future.

Co-authorship network of co-authors of James Robinson

This figure shows the co-authorship network connecting the top 25 collaborators of James Robinson. A scholar is included among the top collaborators of James Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Robinson. James Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Javitt, Daniel C., Cameron S. Carter, Joshua T. Kantrowitz, et al.. (2019). A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. NeuroImage Clinical. 22. 101739–101739. 24 indexed citations

Brunette, Mary F., Kim T. Mueser, Steven F. Babbin, et al.. (2017). Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research. 194. 4–12. 73 indexed citations

Penn, David L., Piper Meyer-Kalos, Kim T. Mueser, et al.. (2016). Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. Schizophrenia Research. 185. 167–172. 33 indexed citations

Kane, John M., Nina R. Schooler, Patricia Marcy, et al.. (2015). The RAISE Early Treatment Program for First-Episode Psychosis. The Journal of Clinical Psychiatry. 76(3). 240–246. 106 indexed citations

Ruglass, Lesia M., Gloria M. Miele, Denise A. Hien, et al.. (2012). Helping Alliance, Retention, and Treatment Outcomes: A Secondary Analysis From the NIDA Clinical Trials Network Women and Trauma Study. Substance Use & Misuse. 47(6). 695–707. 38 indexed citations

Javitt, Daniel C., Robert W. Buchanan, Richard S.E. Keefe, et al.. (2011). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136(1-3). 25–31. 98 indexed citations

Booth, Robert E., Barbara K. Campbell, Susan K. Mikulich‐Gilbertson, et al.. (2010). Reducing HIV-Related Risk Behaviors Among Injection Drug Users in Residential Detoxification. AIDS and Behavior. 15(1). 30–44. 28 indexed citations

Buchanan, Robert W., Richard S.E. Keefe, Jeffrey A. Lieberman, et al.. (2010). A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. Biological Psychiatry. 69(5). 442–449. 128 indexed citations

Campbell, Barbara K., Bret E. Fuller, Eun Sul Lee, et al.. (2009). Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions.. Psychology of Addictive Behaviors. 23(2). 260–270. 29 indexed citations

10.

Hien, Denise A., Huiping Jiang, Aimee Campbell, et al.. (2009). Do Treatment Improvements in PTSD Severity Affect Substance Use Outcomes? A Secondary Analysis From a Randomized Clinical Trial in NIDA's Clinical Trials Network. American Journal of Psychiatry. 167(1). 95–101. 237 indexed citations

11.

Brodie, Jonathan D., Brady G. Case, Stephen L. Dewey, et al.. (2009). Randomized, Double-Blind, Placebo-Controlled Trial of Vigabatrin for the Treatment of Cocaine Dependence in Mexican Parolees. American Journal of Psychiatry. 166(11). 1269–1277. 47 indexed citations

12.

Reid, Malcolm S., Susan C. Sonne, Edward V. Nunes, et al.. (2007). Implementation of a Smoking Cessation Treatment Study at Substance Abuse Rehabilitation Programs: Smoking Behavior and Treatment Feasibility Across Varied Community-based Outpatient Programs. Journal of Addiction Medicine. 1(3). 154–160. 17 indexed citations

13.

Reid, Malcolm S., Susan C. Sonne, Frank Flammino, et al.. (2007). Smoking cessation treatment in community-based substance abuse rehabilitation programs. Journal of Substance Abuse Treatment. 35(1). 68–77. 102 indexed citations

14.

Reid, Malcolm S., Paul Casadonte, Sherryl Baker, et al.. (2005). A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. Addiction. 100(s1). 43–57. 38 indexed citations

15.

Reid, Malcolm S., Burt Angrist, Sherryl Baker, et al.. (2005). A placebo‐controlled screening trial of celecoxib for the treatment of cocaine dependence. Addiction. 100(s1). 32–42. 12 indexed citations

16.

Abikoff, Howard, James J. McGough, Benedetto Vitiello, et al.. (2005). Sequential Pharmacotherapy for Children With Comorbid Attention-Deficit/Hyperactivity and Anxiety Disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 44(5). 418–427. 95 indexed citations

17.

Greenhill, Laurence L., Mark Davies, Prudence W. Fisher, et al.. (2003). Developing Methodologies for Monitoring Long-Term Safety of Psychotropic Medications in Children: Report on the NIMH Conference, September 25, 2000. Journal of the American Academy of Child & Adolescent Psychiatry. 42(6). 651–655. 30 indexed citations

18.

Vitiello, Benedetto, Mark A. Riddle, Michael J. Labellarte, et al.. (2003). How Can We Improve the Assessment of Safety in Child and Adolescent Psychopharmacology?. Journal of the American Academy of Child & Adolescent Psychiatry. 42(6). 634–641. 43 indexed citations

19.

Matteri, Robert L., et al.. (1990). Regulation of the Biopotency of Primate Luteinizing Hormone by Gonadotropin-Releasing Hormone in Vitro and in Vivo1. Biology of Reproduction. 43(6). 1045–1049. 8 indexed citations

20.

Mason, John, et al.. (1968). Urinary Androsterone, Etiocholanolone, and Dehydroepiandrosterone Responses to 72-Hr. Avoidance Sessions in the Monkey. Psychosomatic Medicine. 30(5). 710–720. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact